Selective insolubility of α-synuclein in human lewy body diseases is recapitulated in a transgenic mouse model

American Journal of Pathology

Volumn 159, Issue 6, 2001, Pages 2215-2225

  Kahle, Philipp J ^a   Neumann, Manuela ^a   Ozmen, Laurence ^b   Müller, Veronika ^a   Odoy, Sabine ^a   Okamoto, Noriko ^a   Jacobsen, Helmut ^b   Iwatsubo, Takeshi ^c   Trojanowski, John Q ^d   Takahashi, Hitoshi ^e   Wakabayashi, Koichi ^f   Bogdanovic, Nenad ^g   Riederer, Peter ^h   Kretzschmar, Hans A ^a   Haass, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NIIGATA UNIVERSITY   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

^g KI   (Sweden)

^h UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; IRON; MUTANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; HALLERVORDEN SPATZ DISEASE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SOLUBILITY; TRANSGENIC MOUSE;

EID: 0035191413     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63072-6     Document Type: Article

References (54)

1. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease
2. α-synuclein in Lewy bodies
3. NACP, a presynaptic protein immunoreactivity in Lewy bodies in Parkinson’s disease
4. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders
5. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain α-synuclein immunoreactivity
6. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies
7. α-synuclein accumulates in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies but not in Alzheimer’s disease β-amyloid plaque cores
8. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein
9. Widespread occurrence of α-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies
10. Neurodegeneration with brain iron accumulation, type 1 is characterized by α-β-γ-synuclein neuropathology
11. α-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstemtype Lewy bodies
12. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies
13. Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson’s disease and in dementia with Lewy bodies
14. Multiple system atrophy a sporadic synucleinopathy
15. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease
16. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro
17. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid
18. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation
19. Parkinson’s disease-associated α-synuclein is more fibrillogenic than β,-γ,-synuclein and cannot cross-seed its homologs
20. Accelerated in vitro fibril formation by àmutant α-synuclein linked to early-onset Parkinson disease
21. 53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson’s disease
22. Both familial Parkinson’s disease mutations accelerate α-synuclein aggregation
23. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
24. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease?
25. Mutation in the α-synuclein gene identified in families with Parkinson’s disease
26. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease
27. A Drosophila model of Parkinson’s disease
28. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
29. Neuropathology in mice expressing human α-synuclein
30. Subcellular localization of wild-type and Parkinson’s disease-associated mutant α-synuclein in human and transgenic mouse brain
31. The rat brain synucleins family of proteins transiently associated with neuronal membrane
32. Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14)
33. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch
34. Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system
35. Non-Aβ component of Alzheimer’s disease amyloid (NAC) revisited: NAC and α-synuclein are not associated with Aβ amyloid
36. Identification of two distinct synucleins from human brain
37. The cDNA cloning and ontogeny of mouse α-synuclein
38. Constitutive phosphorylation of the Parkinson’s disease associated α-synuclein
39. Widespread alterations of α-synuclein in multiple system atrophy
40. Muscarinic receptor stimulation induces translocation of an;-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm
41. Ubiquitination of a new form of α-synuclein by parkin from human brain: Implications for Parkinson’s disease
42. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology
43. Differential regulation of a Thy-1 gene in transgenic mice
44. Expression pattern of synucleins (non-Aβ component of Alzheimer’s disease amyloid precursor protein/α synuclein) during murine brain development
45. α-synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining
46. In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin and lipids in Lewy bodies
47. Mutation screening in exons 3 and 4 of α-synuclein in sporadic Parkinson’s and sporadic and familial dementia with Lewy bodies cases
48. α-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease
49. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease
50. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
51. Crosslinking of α-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation?
52. A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly
53. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
54. α-synuclein membrane interactions and lipid specificity